Business Context and Reporting Period
This Form 8-K Current Report was filed by Immunic, Inc. on July 7, 2020, covering events occurring on July 2, 2020, and a scheduled presentation on July 8, 2020. The Company is a Delaware corporation with its principal executive offices in New York, NY, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "IMUX".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events and regulatory disclosures rather than financial performance data.
Material Changes and Corporate Actions
Annual Meeting of Stockholders (July 2, 2020)
- Quorum: 6,172,139 shares were present out of 10,823,951 shares entitled to vote.
- Proposal 1 (Election of Directors): Stockholders elected Dr. Vincent Ossipow and Mr. Jan Van den Bossche to three-year terms expiring in 2023.
- Dr. Ossipow: 5,527,335 votes FOR, 93,396 WITHHELD, 551,408 BROKER NON-VOTES.
- Mr. Van den Bossche: 5,526,774 votes FOR, 93,957 WITHHELD, 551,408 BROKER NON-VOTES.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Baker Tilly Virchow Krause, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- 6,162,934 votes FOR, 4,091 AGAINST, 5,114 ABSTAIN.
Guidance, Outlook, and Regulatory Disclosure
Under Item 7.01 (Regulation FD Disclosure), the Company announced that Dr. Hella Kohlhof, Chief Scientific Officer, will present at the Digital Novel Coronavirus Investment Forum on July 8, 2020. The presentation will cover the clinical development program for IMU-838 as a potential treatment for COVID-19. The presentation is furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the terms and background of the newly elected directors, Dr. Vincent Ossipow and Mr. Jan Van den Bossche.
- Review the content of the presentation (Exhibit 99.1) regarding the clinical development of IMU-838 for COVID-19.
- Confirm the appointment of Baker Tilly Virchow Krause, LLP as the independent auditor for the 2020 fiscal year.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.